Title | Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease. |
Publication Type | Journal Article |
Year of Publication | 2016 |
Authors | Novak, G, Fox, N, Clegg, S, Nielsen, C, Einstein, S, Lu, Y, Tudor, ICristina, Gregg, K, Di, J, Collins, P, Wyman, BT, Yuen, E, Grundman, M, H Brashear, R, Liu, E |
Journal | J Alzheimers Dis |
Volume | 49 |
Issue | 4 |
Pagination | 1123-34 |
Date Published | 2016 |
ISSN | 1875-8908 |
Keywords | Aged, Alzheimer Disease, Antibodies, Monoclonal, Humanized, Apolipoprotein E4, Brain, Double-Blind Method, Female, Heterozygote, Humans, Least-Squares Analysis, Magnetic Resonance Imaging, Male, Nootropic Agents, Organ Size, Severity of Illness Index, Treatment Outcome |
Abstract | BACKGROUND: Bapineuzumab, an anti-amyloid-β monoclonal antibody, was evaluated in two placebo-controlled trials in APOE*ɛ4 carriers and noncarriers, respectively, with Alzheimer's disease. OBJECTIVES: A volumetric magnetic resonance imaging substudy was performed to determine if bapineuzumab altered brain volume rate of change. METHODS: Bapineuzumab dosages included 0.5 mg/kg in carriers and 0.5 or 1.0 mg/kg in noncarriers, every 13 weeks for 78 weeks. Volumetric outcomes included annualized brain, ventricular, and mean hippocampal boundary shift integrals (BBSI; VBSI; HBSI) up to Week 71. Treatment differences were estimated using mixed models for repeated measures. RESULTS: For BBSI and HBSI, there were no significant treatment-related differences within either study, but, compared to pooled carriers and noncarriers receiving placebo, noncarriers receiving1.0 mg/kg bapineuzumab had greater increases in these measures. Bapineuzumab-treated patients showed significantly greater VBSI rates compared with placebo for 0.5 mg/kg in carriers and 1.0 mg/kg (but not 0.5 mg/kg) in noncarriers. CONCLUSIONS: Bapineuzumab produced an increase in ventricular volume compared with placebo. Etiology for this increase is unclear but may be related to amyloid-β clearance or its consequences. |
DOI | 10.3233/JAD-150448 |
Alternate Journal | J. Alzheimers Dis. |
PubMed ID | 26639957 |